

Bacteriophage cocktail shows no toxicity and improves the survival of *Galleria mellonella* infected with *Klebsiella* spp.

Lucy Kelly,¹ Eleanor Jameson²

AUTHOR AFFILIATIONS See affiliation list on p. 13.

ABSTRACT *Klebsiella* spp. are causative agents of healthcare-associated infections in patients who are immunocompromised and use medical devices. The antibiotic resistance crisis has led to an increase in infections caused by these bacteria, which can develop into potentially life-threatening illnesses if not treated swiftly and effectively. Thus, new treatment options for *Klebsiella* are urgently required. Phage therapy can offer an alternative to ineffective antibiotic treatments for antibiotic-resistant bacteria infections. The aim of the present study was to produce a safe and effective phage cocktail treatment against *Klebsiella pneumoniae* and *Klebsiella oxytoca*, both in liquid *in vitro* culture and an *in vivo* *Galleria mellonella* infection model. The phage cocktail was significantly more effective at killing *K. pneumoniae* and *K. oxytoca* strains compared with monophage treatments. Preliminary phage cocktail safety was demonstrated through application in the *in vivo* *G. mellonella* model: where the phage cocktail induced no toxic side effects in *G. mellonella*. In addition, the phage cocktail significantly improved the survival of *G. mellonella* when administered as a prophylactic treatment, compared with controls. In conclusion, our phage cocktail was demonstrated to be safe and effective against *Klebsiella* spp. in the *G. mellonella* infection model. This provides a strong case for future treatment for *Klebsiella* infections, either as an alternative or adjunct to antibiotics.

IMPORTANCE *Klebsiella* infections are a concern in individuals who are immunocompromised and are becoming increasingly difficult to treat with antibiotics due to their drug-resistant properties. Bacteriophage is one potential alternative therapy that could be used to tackle these infections. The present study describes the design of a non-toxic phage cocktail that improved the survival of *Galleria mellonella* infected with *Klebsiella*. This phage cocktail demonstrates potential for the safe and effective treatment of *Klebsiella* infections, as an adjunct or alternative to antibiotics.

KEYWORDS bacteriophage therapy, bacteriophages, *Klebsiella*

Klebsiella spp. are often found as causative agents of healthcare-associated infections, mainly causing urinary tract infections (UTIs) and pneumonia (1, 2). *Klebsiella* have previously been estimated to cause 8% of the total number of nosocomial bacterial infections across Europe and the United States, with *Klebsiella pneumoniae* and *Klebsiella oxytoca* the most prevalent clinically relevant species (3, 4). Of particular concern are *Klebsiella* infections of immunocompromised patients and those who require the use of medical devices such as catheters and ventilators, because infections in this group of patients have mortality rates as high as 80% (1, 5). Gram-negative ESKAPE pathogens, such as *K. pneumoniae*, are currently considered to present the greatest bacterial threat to healthcare, as the emergence of antimicrobial resistant strains, resistant to most, or all, available antibiotics is increasing globally (6). *Klebsiella*, particularly *K. pneumoniae*, accumulate and disseminate multi-drug resistance determinants and are resistant to a wide range of antibiotic classes (7). Over the past two decades, the prevalence of

Editor Kristin N. Parent, Michigan State University, East Lansing, Michigan, USA

Address correspondence to Eleanor Jameson, e.jameson@bangor.ac.uk.

The authors declare no conflict of interest.

See the funding table on p. 14.

Received 7 February 2024

Accepted 22 April 2024

Published 21 May 2024

Copyright © 2024 Kelly and Jameson. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

multi-drug resistant strains of *Klebsiella* has increased throughout the healthcare system, which has led to UTIs, pneumonia, and sepsis which are increasingly difficult to treat using the antibiotics currently available (8, 9). Current approaches used to tackle such infections often focus on the use of a combinatorial approach of antibiotic therapy; however, such treatment has reported a limited efficacy in clinical trials and may be nephrotoxic (10, 11).

Preventing the spread and treating infections caused by antibiotic-resistant strains of *Klebsiella* are challenging prospects; therefore, alternative treatments to traditional antibiotic therapy, such as bacteriophage (phage) therapy, may provide a promising strategy to target these bacteria. A previously published systematic review of multiple phage therapy studies against ESKAPE pathogens reported that phage therapy was safe and effective for treatments caused by these pathogens (12). The aforementioned study reported that phage therapy was effective at degrading biofilms, reducing bacterial burden, encouraging wound healing, and improving patient outcomes. However, despite the urgent requirement for an alternative to antibiotic treatment for *Klebsiella* infections, there are no commercially available phage therapeutics to treat these bacteria.

Phage cocktails are a combination of phages administered as a mixture for phage therapy, as opposed to monophage therapy which uses a single phage (13). Phage cocktails present a number of advantages compared with monophage therapy, such as an increased host range and decreased resistance rates (13). Phage cocktails have demonstrated efficacy compared with monophage therapy in an *in vivo* study of *Klebsiella* infection, with the phage cocktail reducing the emergence of phage-resistant mutants and reducing overall bacterial load (14). A previous study reported the successful use of a phage cocktail to treat a patient with a long-term UTI caused by a multi-drug resistant strain of *K. pneumoniae* (15). The majority of the available data on the clinical efficacy of phage therapy against *Klebsiella* infections comes from administering phage as a last resort treatment, and these compassionate care cases have shown promise, eliminating a chronic UTI, removing *Klebsiella* from the gut, and enhancing wound healing (15–18). A meta-analysis conducted by Al-Anany et al. on the efficacy of phage therapy for UTIs reported ~72% of studies showed that patients improved following phage therapy, while ~99% of patients reported no adverse effects, which suggests that phage therapy is both effective and safe for the treatment of UTIs (19). However, these studies used personalized phage treatment, there is little currently known about how the efficacy of standardized phage cocktail treatment varies across a wider range of *Klebsiella* strains in *in vivo* models of infection, as most currently published studies focus on a single strain of bacteria.

The aim of the present study was to develop a safe and effective *Klebsiella* phage cocktail against a panel of *K. pneumoniae* and *K. oxytoca* strains and examine the efficacy of this treatment in an *in vivo* invertebrate model of *Klebsiella* infection, using *Galleria mellonella* (waxworm moth) larvae.

RESULTS

Virulence index

The virulence index (V_i) of each individual phage, in addition to the phage cocktail (PhC), was determined against the panel of *Klebsiella* strains, to analyze if the PhC was more effective at killing *Klebsiella* compared with monophage therapy treatment (Fig. 1). The V_i of the PhC against Kp30104 was significantly higher compared with phages 7, 10, 12, and 67. Furthermore, the PhC was significantly more effective at killing Kp170723 compared to all of the monophage treatments tested. The PhC was significantly more effective at killing Ko170748 compared with phages 7, 10, 44, and 64. There was no significant difference observed between the V_i of the PhC and single phage against Kp13442 and Kp171266. None of the phages tested in this study was previously shown to infect Kp13442 (20).




FIG 1 Virulence index of single phage and phage cocktail against (A) *Kp30104*, (B) *Kp13442*, (C) *Kp170723*, (D) *Ko170748*, and (E) *Ko171266*. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ vs phage cocktail.

Endotoxin testing and removal

Endotoxin testing is an important step in the process of PhC preparation as endotoxin present in phage preparations is a highly immunogenic compound that can cause endotoxic shock when present at high quantities (21). The concentration of endotoxin present in the PhC before and after endotoxin removal is presented in Table 1. The

TABLE 1 Concentration of endotoxin in phage cocktail preparation before and after endotoxin removal

Endotoxin levels pre-endotoxin removal column (EU/10 ⁹ PFU)	Endotoxin levels post-endotoxin removal column (EU/10 ⁹ PFU)
1.589 × 10 ³	7.040 × 10 ¹

maximum accepted level of endotoxin present in a medicinal product is 0.2 EU/kg/h for intrathecal administration or 5 EU/kg/h for intravenous administration, which is equivalent to 1.6×10^3 EU/10⁹ PFU of phage treatment (22–24). As the level of endotoxin present in the PhC preparation after endotoxin removal was 70.41 EU/10⁹ PFU, the PhC preparation was deemed safe for use in the *G. mellonella* model.

LD₅₀ of *Klebsiella* in *G. mellonella* larvae

The survival of *G. mellonella* larvae injected with different *Klebsiella* strains was monitored for 5 days to determine the LD₅₀ (lethal dose for 50% of the subjects) of each bacterial strain (Fig. 2). Based on these survival curves, the LD₅₀ of each of the *K. pneumoniae* and *K. oxytoca* strains was calculated (Table 2). This showed that the optimal dose of *K. pneumoniae* was 2×10^4 to 5×10^5 and for *K. oxytoca*, it was 1×10^6 to obtain LD₅₀.

Survival of *G. mellonella* infected with *Klebsiella* with prophylactic phage therapy

Prophylactic PhC phage therapy was administered to larvae to determine if this treatment regime was effective at rescuing *G. mellonella* larvae from infection and death caused by *Klebsiella* infection. Prophylactic PhC was administered to the larvae 4 h before infection with *Klebsiella*, and survival of the larvae was monitored for 5 days (Fig. 3). The survival of larvae prophylactically treated with PhC (multiplicity of infection [MOI] = 1) and infected with *Kp30104* was significantly increased, compared with bacteria-only controls. Prophylactic PhC (MOI = 1, 10, and 100) of *Kp170723*-infected and *Ko170748*-infected larvae significantly increased survival compared with bacteria-only controls. The survival of larvae prophylactically treated with PhC (MOI = 10 and 100) and infected with *Ko171266* was significantly increased, compared with bacteria-only controls. There was no significant difference observed in the survival of phage-injected larvae compared with controls, which indicated that the PhC did not induce death in these larvae.

Survival of *G. mellonella* infected with *Klebsiella* treated with co-injection phage therapy

Co-injection of *Klebsiella* and PhC was administered to larvae to determine if this treatment regime could prevent infection and death of larvae injected with *Klebsiella*. PhC and *Klebsiella* were combined and injected into larvae, and survival of *G. mellonella* was monitored for 5 days (Fig. 4). Co-injection of PhC (MOI = 1, 10, and 100) significantly improved survival of larvae injected with *Kp30104*, compared with bacteria-only controls. The survival of larvae treated with PhC (MOI = 100) and *Ko170748* was significantly improved compared with bacteria-only controls. There was no significant difference observed in the survival of phage-injected larvae compared with controls, which indicated that the PhC did not induce death in these larvae.

Survival of *G. mellonella* infected with *Klebsiella* treated with remedial phage therapy

Remedial phage therapy with the PhC was administered to *G. mellonella* larvae in order to analyze if this treatment regime was effective at preventing death caused by *Klebsiella* infection. The PhC was administered 4 h following *Klebsiella* injection of the larvae, and survival of *G. mellonella* was monitored for 5 days (Fig. 5). Remedial PhC (MOI = 10) significantly improved the survival of larvae injected with *Kp30104*, compared with




FIG 2 Survival curves of LD₅₀ doses of (A) *Kp*30104, (B) *Kp*13442, (C) *Kp*170723, (D) *Ko*171266, and (E) *Ko*170748 in *Galleria mellonella* larvae after 5 days.

TABLE 2 LD₅₀ dose of different *Klebsiella* strains in *Galleria mellonella*

Strain	LD ₅₀ (CFU/mL)
Kp30104	5 × 10 ⁵
Kp13442	2 × 10 ⁴
Kp170723	2 × 10 ⁵
Ko170748	1 × 10 ⁶
Ko171266	1 × 10 ⁶

bacteria-only controls. There was no significant difference observed in the survival of phage-injected larvae compared with controls, which indicated that the PhC did not induce death in these larvae.

DISCUSSION

Our study confirms the efficacy of a phage cocktail (PhC) treatment against *K. pneumoniae* and *K. oxytoca* strains in a *G. mellonella* infection model with prophylactic phage therapy, showing no adverse effects. A number of previously published studies have characterized effective monophage or PhC treatments against a single strain, sequence type, or capsule type of *Klebsiella*, but few have produced an effective and safe PhC treatment against multiple strains and species of *Klebsiella* (25–29). To the best of our knowledge, no studies have previously reported on the efficacy of a PhC treatment on both culture collection and clinically isolated strains of *Klebsiella*.

The phages selected for inclusion into the PhC treatment were genetically distinct and had the widest host range available from a panel of previously characterized phages (20). This PhC consisted of phages that spanned six phylogenetic groups, five families, three subfamilies, six genera, four sources of isolation, and six capsule type targets (20). This strategy was selected for the design of the PhC, as a combination of genetically distinct phages is more likely to be effective at removing target bacteria compared with monophage treatment, if a PhC contains phage with different host receptor targets, the host is unlikely to gain multiple mechanisms of resistance simultaneously without significantly impairing its own fitness (13). Our PhC was effective at killing four out of five *Klebsiella* strains tested, with the exception of Kp13442, a strain resistant to all individual phages tested (20). Kp13442 was tested in this study to determine if a PhC treatment would demonstrate synergy against a phage-resistant strain of bacteria under *in vivo* conditions; however, this was not the case. Despite the PhC demonstrating a lack of efficacy against Kp13442, there was some improvement observed in the survival rates of *G. mellonella* infected with this strain that received prophylactic PhC treatment. This may potentially be due to the time period between PhC injection and subsequent challenge with the bacteria being long enough to allow the PhC treatment to circulate throughout the larvae and adjust to the incubation temperature in time to optimally infect incoming bacteria (30, 31). Furthermore, while Kp13442 was insensitive to killing by the PhC, the PhC could potentially infect the bacteria and make the bacterium less virulent, which could consequently enable the larval immune system to more effectively tackle infection with Kp13442 (32).

The Vi results demonstrated that the PhC was more effective at killing Kp30104, Kp170723, and Ko170748 than a number of the monophage treatments tested, which suggested that the PhC has the potential to be a more effective treatment against these *Klebsiella* strains than monophage therapy. The PhC was the most effective against Kp170723 compared with the single phage treatments, which indicated synergistic killing effects between the phages in the cocktail, despite no monophage treatment demonstrating a high Vi against Kp170723.

Of the three PhC phage therapy dosing regimes administered here, the most effective at killing a range of *Klebsiella* strains in the invertebrate model was prophylaxis, followed by co-injection. Prophylactic phage therapy was effective at increasing the survival of *G. mellonella* infected with Kp170723 and Ko170748, two clinically isolated strains of *Klebsiella*, which highlighted the potential for this PhC to be used to treat clinical




FIG 3 Survival curves of prophylactic phage cocktail treatment against *Galleria mellonella* infected with (A) *Kp*30104, (B) *Kp*13442, (C) *Kp*170723, (D) *Ko*170748, and (E) *Ko*171266.




FIG 4 Survival curves of co-injection phage cocktail treatment against *Galleria mellonella* infected with (A) *Kp*30104, (B) *Kp*13442, (C) *Kp*170723, (D) *Ko*170748, and (E) *Ko*171266.




FIG 5 Survival curves of remedial phage cocktail treatment against *Galleria mellonella* infected with (A) *Kp13442*, (B) *Kp30104*, (C) *Kp170723*, (D) *Ko170748*, and (E) *Ko171266*.

infections caused by these strains. This phage therapy regime was also effective at increasing the survival of *Kp30104*. Prophylactic phage therapy could potentially act as a type of intervention therapy, preventing disease in patients when used prior to surgery or in patients who require the use of medical devices. Prophylactic phage therapy aims to prevent colonization and infection by bacteria before they can cause harm, as opposed to treating an established infection (33–35). This treatment regime presents

an attractive option to tackle healthcare-associated *Klebsiella* infections, as these are often a result of the contamination of medical devices, such as catheters and ventilators (36). Co-injection of phage and bacteria is indicative of a clinical situation whereby phage therapy is administered to a patient at the same time the patient may potentially be colonized by *Klebsiella*, for example, upon admission to the hospital or the use of a medical device. Co-injection of the higher doses of PhC in the present study was effective at increasing the survival of *G. mellonella* injected with *Kp30104* and *Kp170723*. The success of this co-injection regime of phage therapy may potentially be due to an increased frequency of bacteria-phage interactions, as the phage was combined directly with bacteria before injection into the larvae. This may enable the phage to more rapidly adhere to the invading bacteria, negating the need for chance encounters between phage and bacteria during systemic circulation in the larvae, to enable phage infection, proliferation, and killing of the target bacteria (37). Remedial phage therapy is a clinically relevant scenario for PhC administration to a patient with an ongoing *Klebsiella* infection. In the present study, remedial phage therapy was the least successful regime tested; however, one concentration of the PhC was effective at increasing the survival of larvae infected with *Kp30104*. Therefore, remedial PhC phage therapy shows potential but requires further optimization of the dose, timing, or PhC formulation to maximize efficacy. This observed lower efficacy of remedial phage therapy compared with prophylactic or co-injection phage therapy is consistent with previously published studies on the efficacy of different phage therapy regimes in *G. mellonella* (38, 39).

A previous study on the use of a prophylactic PhC against several bacterial species, including *K. pneumoniae*, was effective against infections in a mouse model (40). The pretreatment of medical devices has previously been reported to be highly effective at reducing colonization of devices by pathogens and preventing biofilm formation (41). The data presented in the present study add to a growing body of literature that supports the efficacy of prophylactic phage therapy for the prevention of bacterial infections. Furthermore, this demonstrates that phages can persist in an invertebrate host, were not degraded by the *G. mellonella* innate immune system, or were inactivated through binding to organic matter. Therefore, prophylactic phage therapy, at the treatment concentration provided in the present study, circulated throughout the *G. mellonella* system and encountered host bacteria.

The higher doses of PhC therapy administered were most effective at increasing the survival of *G. mellonella* compared with the lower doses of PhC. This association has also been reported in previous studies of phage therapy in *G. mellonella* (38, 42, 43). This is potentially due to increased bacteria-phage interactions that may occur as a result of an increased concentration of phage compared with low-dose phage therapy (13).

One of the aims of the present study was to design a safe PhC for use in an *in vivo* model of *Klebsiella* infection. The survival of the control phage-only groups of larvae was comparable to the untreated and injection trauma controls in each phage therapy regime, which demonstrated that the PhC was not innately toxic and could be carried forward safely into more complex infection models, such as mammalian models of *Klebsiella* infection. The acquisition of preliminary safety data is an important part of phage therapy design, as patient safety is an essential pillar for the introduction of phage therapy in human clinical trials (44).

Further development of this PhC treatment could include the testing of multiple doses of PhC therapy, as a single dose of the PhC was tested in the present study, as multiple doses of PhC may potentially increase the efficacy of the treatment. Additionally, the impact of PhC as an adjunct to antibiotic treatment is an important consideration for future phage therapy studies. Phage-antibiotic synergy has previously been reported and has shown promise in treating bacterial infections, including those caused by *K. pneumoniae* (45–47).

Our PhC is a step forward, it prevents infection by multiple *Klebsiella* strains with a pre-characterized, off-the-shelf formulation, compared with treating sick patients by first testing individual phages in expensive, time-consuming personalized phage therapy. As

TABLE 3 Details of *Klebsiella* strains used in the present study

Strain name	Origin	Isolation source	Capsule type (KL)
<i>Klebsiella pneumoniae</i> 30104 (Kp30104)	DSMZ culture collection	Human blood	KL3
<i>Klebsiella pneumoniae</i> 13442 (Kp13442)	NCTC culture collection	Hospital	KL110
<i>Klebsiella pneumoniae</i> 170723 (Kp170723)	Clinical isolate	Urine	KL2
<i>Klebsiella oxytoca</i> 170748 (Ko170748)	Clinical isolate	Catheter specimen urine	O1v1
<i>Klebsiella oxytoca</i> 171266 (Ko171266)	Clinical isolate	Urostomy urine	OL104

with any clinical measure, one of the major obstacles with this therapy is the insensitivity of an infecting pathogen to treatment. The PhC used in the present study was infective against Kp13442 (K110). Our previous work demonstrated the difficulty of isolating phages that infect a broad range of *Klebsiella* hosts and K-types, and also highlighted Kp13442 as the most phage-resistant strain tested, as it was insensitive to 29/30 phages (20). Fortunately, K110 is not a prevalent clinical *Klebsiella* K-type (48). For patients carrying an insensitive *Klebsiella* strain, the PhC treatment presented in the present study may be ineffective, and these bacteria may potentially need to be treated with antibiotics, or a Magisterial phage treatment (49).

To conclude, the present study demonstrates the design of a safe and effective PhC treatment against *K. pneumoniae* and *K. oxytoca*. The PhC was effective at increasing the survival of *G. mellonella* infected with both culture collection and clinically isolated strains of *Klebsiella*. Therefore, the PhC presented in this study shows potential for the future treatment of *Klebsiella* infections, as an alternative or adjunct to antibiotic treatments.

MATERIALS AND METHODS

Bacterial culture

The details of the bacterial strains used in this study are presented in Table 3. *Klebsiella* strains were maintained on Lysogeny broth (LB; Merck) agar plates. As required, liquid cultures were prepared by inoculating 10 mL of LB with a single colony of bacteria and incubating overnight at 37°C and 180 rpm shaking.

Bacteriophage propagation

The details of the bacteriophage used in this study are presented in Tables 4 and 5, and the host range of these phages is presented in Table 6. A 10- μ L volume of phage lysate was added to a log-phase culture of the *Klebsiella* host strain in LB supplemented with 5 mM CaCl₂ (Thermo Fisher Scientific) and 5 mM MgCl₂ (Thermo Fisher Scientific) and incubated at 37°C with 180 rpm shaking overnight. Phage lysate was centrifuged at 3,220 $\times g$ for 20 min at room temperature, and the supernatant was filtered through

TABLE 4 Details of bacteriophage strains used in the present study^a

Phage name	Lab ID	Isolation source	Isolation strain	Capsule target (KL)	Accession no.
<i>Klebsiella</i> phage vB KaS-Ahsoka	7	Slurry, slurry tank, UK	<i>Klebsiella aerogenes</i> DSM 30053	–	PRJEB40160
<i>Klebsiella</i> phage vB KppS-Totoro	10	Estuary, Jelitkowo, Poland	<i>Klebsiella pneumoniae</i> DSM 30104	KL3	PRJEB40166
<i>Klebsiella</i> phage vB KoM-Pickle	12	Estuary, Jelitkowo, Poland	<i>Klebsiella oxytoca</i> DSM 25736	KL74	PRJEB40176
<i>Klebsiella</i> phage vB KqM-Weterburg	39	Raw sewage, Spernal sewage works, UK	<i>Klebsiella quasipneumoniae</i> DSM 28211	KL35	PRJEB40173
<i>Klebsiella</i> phage vB KqP-Goliath	44	Raw sewage, Spernal sewage works, UK	<i>Klebsiella quasipneumoniae</i> DSM 700603	KL53	PRJEB40163
<i>Klebsiella</i> phage vB KpM-Wobble	64	Mixed liquor sewage, Spernal sewage works, UK	<i>Klebsiella pneumoniae</i> 170958	KL28	PRJEB40182
<i>Klebsiella</i> phage vB KpM-KalD	67	Mixed liquor sewage, Spernal sewage works, UK	<i>Klebsiella pneumoniae</i> DSM 13439	KL14	PRJEB40178

^a–, a capsule could not be resolved.

TABLE 5 Taxonomy of phage used in the present study

Phage name	Taxonomic group	Taxonomy		
		Family	Subfamily	Genus
<i>Klebsiella</i> phage vB KaS-Ahsoka	C	<i>Drexelviriidae</i>	<i>Tunavirinae</i>	Unclassified
<i>Klebsiella</i> phage vB KppS-Totoro	F	<i>Demereciviridae</i>	–	<i>Sugarlandvirus</i>
<i>Klebsiella</i> phage vB KoM-Pickle	H	<i>Straboviridae</i>	–	<i>Slopekivirus</i>
<i>Klebsiella</i> phage vB KqM-Weterburg	G	<i>Ackermannviridae</i>	–	<i>Taipeivirus</i>
<i>Klebsiella</i> phage vB KqP-Goliath	E	<i>Autographiviridae</i>	<i>Slopekvirinae</i>	<i>Drulisvirus</i>
<i>Klebsiella</i> phage vB KpM-Wobble	I	<i>Straboviridae</i>	<i>Tevenvirinae</i>	<i>Jiaodavirus</i>
<i>Klebsiella</i> phage vB KpM-KalD	H	<i>Straboviridae</i>	<i>Tevenvirinae</i>	<i>Slopekivirus</i>

a 0.2- μ m syringe filter (Sarstedt) to remove host cells. Phage was enumerated through serial dilution, then mixing 50 μ L of the diluent with 125 μ L of log-phase host bacteria, followed by incubation at room temperature for 10 min. Each dilution was mixed with 625 μ L of LB top agar (0.4% agar) supplemented with 5 mM CaCl₂ and 5 mM MgCl₂ and immediately plated on six-well plates containing solidified 1% LB agar. The solidified overlay plates were incubated at 37°C overnight, and phage plaques were enumerated.

Bacteria-phage growth curves

The virulence index (Vi) was used to quantify the efficacy of a single phage and the phage cocktail against the *Klebsiella* strains in this study (50). An overnight culture of *Klebsiella* was refreshed 1:100 in LB and incubated at 37°C with 180 rpm shaking until log-phase growth was achieved. Phage was serially diluted from an MOI of 1 to 10⁻⁷ and 10 μ L of each phage dilution was added to 190 μ L of *Klebsiella* in a 96-well plate. The optical density of the samples was measured at 600 nm every 10 min for 18 h at 37°C using a FLUOstar Omega Microplate Reader (BMG Labtech). The Vi of each sample was then calculated.

Endotoxin testing and removal

Endotoxin testing of phage lysates was performed using the Pierce Chromogenic Endotoxin Quant Kit (Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. The Pierce High Capacity Endotoxin Removal Spin Columns (Thermo Fisher Scientific, Inc.) were used to remove endotoxin from phage lysates.

Maintenance of *G. mellonella*

G. mellonella larvae (LiveFood UK Ltd.) were obtained, stored at 4°C immediately upon arrival, and used within 2 days of delivery. Larvae were individually weighed and those with a weight between 0.20 and 0.30 g were selected for further experiments. Groups of 10 larvae were randomly assigned to each treatment condition and stored in Petri dishes throughout the experiment.

Determining the LD₅₀ of *Klebsiella* strains in *G. mellonella*

The LD₅₀ of each *Klebsiella* strain was calculated over a 5-day period. An overnight culture of *Klebsiella* was diluted 1:100 in LB and incubated at 37°C with 180 rpm shaking

TABLE 6 Host range of phage used in the present study^a

<i>Klebsiella</i> strain	Phage 7	Phage 10	Phage 12	Phage 39	Phage 44	Phage 64	Phage 67
Kp30104	Yes	Yes	Yes	Yes	–	Yes	Yes
Kp13442	–	–	–	–	–	–	–
Kp170723	–	–	Yes	Yes	Yes	Yes	Yes
Ko170748	–	Yes	Yes	–	–	–	Yes
Ko171266	–	Yes	Yes	–	–	–	Yes

^a–, no infection of a host was detected in single-phage tests.

until log-phase growth was achieved. Cultures were centrifuged twice at $3,220 \times g$ for 15 min at room temperature, cell pellets were washed with PBS, and the final pellet was re-suspended and serially diluted in PBS. *G. mellonella* injection sites were sterilized using 70% ethanol. A 10- μ L dose of *Klebsiella* was injected into the last left proleg of the larvae using a 30 G needle on a Hamilton 500 μ L gastight syringe fitted with a Hamilton PB600-1 repeating dispenser. The *Kp170723* doses used were 10^5 , 10^4 , 10^3 , and 10^2 CFU/larvae. The doses for the remaining four *Klebsiella* strains were 10^7 , 10^6 , 10^5 , and 10^4 CFU/larvae. Negative controls of PBS-injected and untreated larvae were included in each experiment. Larvae were incubated at 37°C in the dark for 5 days and remained unfed. Larval survival was monitored daily, and larvae were scored as either live or dead every 24 h, with larvae classified as dead once they turned black and immobile. Dead larvae were removed each day. At the end of the experiments, larvae were euthanized by placing them in a -20°C freezer for <2 h, then moved to a -80°C freezer for overnight storage before disposal. The LD₅₀ dose calculated was used to infect larvae in subsequent experiments.

Phage therapy of *Klebsiella*-infected *G. mellonella*

Three different PhC phage therapy regimens (prophylaxis, co-injection, and remedial treatment), along with bacteria-only and phage-only controls, and PBS-injected and untreated larvae were prepared. A 10- μ L dose of *Klebsiella* was used in each of the bacteria-treated larvae. PhC dilutions were prepared in PBS to an MOI of 1, 10, or 100 for each *Klebsiella* strain to be tested. A 10- μ L dose of PhC was used in each of the phage-treated larvae.

The phage therapy regimens were designed as follows: (i) prophylaxis, PhC injected at 0 h and *Klebsiella* injected at 4 h; (ii) co-injection, PhC, and *Klebsiella* were mixed and immediately injected at 0 h; and (iii) remedial, *Klebsiella* injected at 0 h and PhC injected at 4 h. In the treatment groups where two injections were required (prophylaxis and remedial therapy), the first injection was in the last left proleg and the second injection was in the last right proleg. The survival of larvae was monitored over 5 days.

Statistical analysis

Statistical analysis and data visualization were performed using GraphPad Prism (version 9.5.1; Dotmatics). One-way analysis of variance with Tukey's post-hoc test was used to determine statistically significant differences between multiple groups. Kaplan-Meier survival curves were produced, and a log-rank Mantel-Cox test was performed to determine the statistical significance between survival curves. Data are presented as the mean \pm standard deviation of three independent experiments. $P < 0.05$ was considered to indicate a statistically significant difference.

ACKNOWLEDGMENTS

The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication. This work was partially supported by the MIBTP DTP PhD studentship awarded to L.K. and by a Warwick Integrative Synthetic Biology (WISB) early career fellowship, funded jointly by BBSRC/EPSRC to E.J., grant ref: BB/M017982/1.

AUTHOR AFFILIATIONS

¹School of Life Sciences, University of Warwick, Coventry, United Kingdom

²School of Environmental and Natural Sciences, Bangor University, Gwynedd, United Kingdom

AUTHOR ORCID*s*Lucy Kelly  <http://orcid.org/0000-0002-5894-3525>Eleanor Jameson  <http://orcid.org/0000-0001-6427-3794>

FUNDING

Funder	Grant(s)	Author(s)
UKRI Biotechnology and Biological Sciences Research Council (BBSRC)	MIBTP studentship	Lucy Kelly

DATA AVAILABILITY

All phage sequence data have previously been made available, and accession numbers are provided in Table 4.

These accession numbers can be retrieved at the European Nucleotide Archive at <https://www.ebi.ac.uk/ena/browser/search>.

REFERENCES

- Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, McAllister-Hollod L, Nadle J, Ray SM, Thompson DL, Wilson LE, Fridkin SK, Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. 2014. Multistate point-prevalence survey of health care-associated infections. *N Engl J Med* 370:1198–1208. <https://doi.org/10.1056/NEJMoa1306801>
- Podschun R, Pietsch S, Höller C, Ullmann U. 2001. Incidence of *Klebsiella* species in surface waters and their expression of virulence factors. *Appl Environ Microbiol* 67:3325–3327. <https://doi.org/10.1128/AEM.67.7.3325-3327.2001>
- Janda JM. 2015. The genus *Klebsiella*: an ever-expanding panorama of infections, disease-associated syndromes, and problems for clinical microbiologist. *Clin Microbiol Case Rep* 1:2.
- Podschun R, Ullmann U. 1998. *Klebsiella spp.* as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. *Clin Microbiol Rev* 11:589–603. <https://doi.org/10.1128/CMR.11.4.589>
- Shankar C, Nabarro LE, Anandan S, Ravi R, Babu P, Munusamy E, Jeyaseelan V, Rupali P, Verghese VP, Veeraraghavan B. 2018. Extremely high mortality rates in patients with carbapenem-resistant, hypermucoviscous *Klebsiella pneumoniae* blood stream infections. *J Assoc Physicians India* 66:13–16.
- de Man TJB, Lutgring JD, Lonsway DR, Anderson KF, Kiehlauch JA, Chen L, Walters MS, Sjölund-Karlsson M, Rasheed JK, Kallen A, Halpin AL. 2018. Genomic analysis of a pan-resistant isolate of *Klebsiella pneumoniae*, United States 2016. *mBio* 9:10. <https://doi.org/10.1128/mBio.00440-18>
- Pendleton JN, Gorman SP, Gilmore BF. 2013. Clinical relevance of the ESKAPE pathogens. *Expert Rev Anti Infect Ther* 11:297–308. <https://doi.org/10.1586/eri.13.12>
- Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! an update from the infectious diseases society of America. *Clin Infect Dis* 48:1–12. <https://doi.org/10.1086/595011>
- Kuehn BM. 2013. Nightmare" bacteria on the rise in US hospitals, long-term care facilities. *JAMA* 309:1573. <https://doi.org/10.1001/jama.2013.2922>
- Kaur CP, Vadivelu J, Chandramathi S. 2018. Impact of *Klebsiella pneumoniae* in lower gastrointestinal tract diseases. *J Dig Dis* 19:262–271. <https://doi.org/10.1111/1751-2980.12595>
- Tumbarello M, Viale P, Viscoli C, Treccarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M. 2012. Predictors of mortality in bloodstream infections caused by *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*: importance of combination therapy. *Clin Infect Dis* 55:943–950. <https://doi.org/10.1093/cid/cis588>
- El Haddad L, Harb CP, Gebara MA, Stibich MA, Chemaly RF. 2019. A systematic and critical review of bacteriophage therapy against multidrug-resistant ESKAPE organisms in humans. *Clin Infect Dis* 69:167–178. <https://doi.org/10.1093/cid/ciy947>
- Chan BK, Abedon ST. 2012. Phage therapy pharmacology: phage cocktails, p 1–23. In *Advances in applied Microbiology*. Elsevier.
- Chadha P, Katara OP, Chhibber S. 2016. *In vivo* efficacy of single phage versus phage cocktail in resolving burn wound infection in BALB/c mice. *Microb Pathog* 99:68–77. <https://doi.org/10.1016/j.micpath.2016.08.001>
- Qin J, Wu N, Bao J, Shi X, Ou H, Ye S, Zhao W, Wei Z, Cai J, Li L, Guo M, Weng J, Lu H, Tan D, Zhang J, Huang Q, Zhu Z, Shi Y, Hu C, Guo X, Zhu T. 2020. Heterogeneous *Klebsiella pneumoniae* co-infections complicate personalized bacteriophage therapy. *Front Cell Infect Microbiol* 10:608402. <https://doi.org/10.3389/fcimb.2020.608402>
- Kuipers S, Ruth MM, Mientjes M, de Sévaux RGL, van Ingen J. 2019. A Dutch case report of successful treatment of chronic relapsing urinary tract infection with bacteriophages in a renal transplant patient. *Antimicrob Agents Chemother* 64:10. <https://doi.org/10.1128/AAC.01281-19>
- Corbellino M, Kieffer N, Kutateladze M, Balarjshvili N, Leshkasheli L, Askilashvili L, Tsertsvadze G, Rimoldi SG, Nizharadze D, Hoyle N, Nadareishvili L, Antinori S, Pagani C, Scorza DG, Romanò ALL, Ardizzone S, Danelli P, Gismondo MR, Galli M, Nordmann P, Poirel L. 2020. Eradication of a multidrug-resistant, carbapenemase-producing *Klebsiella pneumoniae* isolate following oral and intra-rectal therapy with a custom made, lytic bacteriophage preparation. *Clin Infect Dis* 70:1998–2001. <https://doi.org/10.1093/cid/ciz782>
- Cano EJ, Cafilisch KM, Bollyky PL, Van Belleghem JD, Patel R, Fackler J, Brownstein MJ, Horne B, Biswas B, Henry M, Malagon F, Lewallen DG, Suh GA. 2021. Phage therapy for limb-threatening prosthetic knee *Klebsiella pneumoniae* infection: case report and *in vitro* characterization of anti-biofilm activity. *Clin Infect Dis* 73:e144–e151. <https://doi.org/10.1093/cid/ciaa705>
- Al-Anany AM, Hooey PB, Cook JD, Burrows LL, Martyniuk J, Hynes AP, German GJ. 2023. Phage therapy in the management of urinary tract infections: a comprehensive systematic review. *Phage* (New Rochelle) 4:112–127. <https://doi.org/10.1089/phage.2023.0024>
- Townsend EM, Kelly L, Gannon L, Muscatt G, Dunstan R, Michniewski S, Sapkota H, Kiljunen SJ, Kolsi A, Skurnik M, Lithgow T, Millard AD, Jameson E. 2021. Isolation and characterization of *Klebsiella* phages for phage therapy. *Phage* (New Rochelle) 2:26–42. <https://doi.org/10.1089/phage.2020.0046>
- Raetz CRH, Whitfield C. 2002. Lipopolysaccharide endotoxins. *Annu Rev Biochem* 71:635–700. <https://doi.org/10.1146/annurev.biochem.71.110601.135414>
- Europe, C.o. 2005. Bacterial endotoxins. 5th ed. Vol. 5. Council of Europe, Strasbourg.
- Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, Barr JJ, Reed SL, Rohwer F, Benler S, et al. 2017. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a

- patient with a disseminated resistant *Acinetobacter baumannii* infection. *Antimicrob Agents Chemother* 61:10. <https://doi.org/10.1128/AAC.00954-17>
24. Hietala V, Horsma-Heikkinen J, Carron A, Skurnik M, Kiljunen S. 2019. The removal of endo- and enterotoxins from bacteriophage preparations. *Front Microbiol* 10:1674. <https://doi.org/10.3389/fmicb.2019.01674>
 25. Singh S, Wilksch JJ, Dunstan RA, Mularski A, Wang N, Hocking D, Jebeli L, Cao H, Clements A, Jenney AWJ, Lithgow T, Strugnell RA. 2022. LPS O antigen plays a key role in *Klebsiella pneumoniae* capsule retention. *Microbiol Spectr* 10:e0151721. <https://doi.org/10.1128/spectrum.01517-21>
 26. Zurabov F, Zhilenkov E. 2021. Characterization of four virulent *Klebsiella pneumoniae* bacteriophages, and evaluation of their potential use in complex phage preparation. *Virol J* 18:9. <https://doi.org/10.1186/s12985-020-01485-w>
 27. Manohar P, Tamhankar AJ, Lundborg CS, Nachimuthu R. 2019. Therapeutic characterization and efficacy of bacteriophage cocktails infecting *Escherichia coli*, *Klebsiella pneumoniae*, and enterobacter species. *Front. Microbiol* 10:574. <https://doi.org/10.3389/fmicb.2019.00574>
 28. Martins W, Li M, Sands K, Lenzi MH, Portal E, Mathias J, Dantas PP, Migliavacca R, Hunter JR, Medeiros EA, Gales AC, Toleman MA. 2022. Effective phage cocktail to combat the rising incidence of extensively drug-resistant *Klebsiella pneumoniae* sequence type 16. *Emerg Microbes Infect* 11:1015–1023. <https://doi.org/10.1080/22221751.2022.2051752>
 29. Tan D, Zhang Y, Cheng M, Le S, Gu J, Bao J, Qin J, Guo X, Zhu T. 2019. Characterization of *Klebsiella pneumoniae* ST11 isolates and their interactions with lytic phages. *Viruses* 11:1080. <https://doi.org/10.3390/v11111080>
 30. Taj M. 2014. Effect of dilution, temperature and pH on the lysis activity of T4 phage against *E. coli* BI21
 31. Jończyk E, Klak M, Międzybrodzki R, Górski A. 2011. The influence of external factors on bacteriophages. *Folia Microbiol (Praha)* 56:191–200. <https://doi.org/10.1007/s12223-011-0039-8>
 32. León M, Bastías R. 2015. Virulence reduction in bacteriophage resistant bacteria. *Front Microbiol* 6:343. <https://doi.org/10.3389/fmicb.2015.00343>
 33. Prazak J, Valente L, Iten M, Grandgirard D, Leib SL, Jakob SM, Haenggig M, Que Y-A, Cameron DR. 2020. Nebulized bacteriophages for prophylaxis of experimental ventilator-associated pneumonia due to methicillin-resistant *Staphylococcus aureus*. *Crit Care Med* 48:1042–1046. <https://doi.org/10.1097/CCM.0000000000004352>
 34. SAYAMOV RM. 1963. Treatment and prophylaxis of cholera with bacteriophage. *Bull World Health Organ* 28:361–367.
 35. Kutateladze M, Adamia R. 2008. Phage therapy experience at the Eliava Institute. *Med Mal Infect* 38:426–430. <https://doi.org/10.1016/j.medmal.2008.06.023>
 36. Percival SL, Suleman L, Vuotto C, Donelli G. 2015. Healthcare-associated infections, medical devices and biofilms: risk, tolerance and control. *J Med Microbiol* 64:323–334. <https://doi.org/10.1099/jmm.0.000032>
 37. Abedon ST, Thomas-Abedon C. 2010. Phage therapy pharmacology. *Curr Pharm Biotechnol* 11:28–47. <https://doi.org/10.2174/138920110790725410>
 38. Beeton ML, Alves DR, Enright MC, Jenkins ATA. 2015. Assessing phage therapy against *Pseudomonas aeruginosa* using a *Galleria mellonella* infection model. *Int J Antimicrob Agents* 46:196–200. <https://doi.org/10.1016/j.ijantimicag.2015.04.005>
 39. Nale JY, Chutia M, Carr P, Hickenbotham PT, Clokie MRJ. 2016. Get in early; biofilm and wax moth (*Galleria mellonella*) models reveal new insights into the therapeutic potential of *Clostridium difficile* bacteriophages. *Front Microbiol* 7:1383. <https://doi.org/10.3389/fmicb.2016.01383>
 40. Aleshkin AV, Volozhantsev NV, Svetoch EA, Kiseleva IA, Rubal'sky EO, Afanas'ev SS, Borzilov AI, Zatevalov AM, Vasil'ev DA, Zolotukhin SN, et al. 2016. Bacteriophages as probiotics: phage-based Probiotic dietary supplement in prophylaxis against foodborne infections. *Infekc bolezni* 14:31–40. <https://doi.org/10.20953/1729-9225-2016-2-31-40>
 41. Townsend EM, Moat J, Jameson E. 2020. CAUTI's next top model—model dependent *Klebsiella* biofilm inhibition by bacteriophages and antimicrobials. *Biofilm* 2:100038. <https://doi.org/10.1016/j.biofilm.2020.100038>
 42. Pu M, Li Y, Han P, Lin W, Geng R, Qu F, An X, Song L, Tong Y, Zhang S, Cai Z, Fan H. 2022. Genomic characterization of a new phage BUCT541 against *Klebsiella pneumoniae* K1-ST23 and efficacy assessment in mouse and *Galleria mellonella* larvae. *Front Microbiol* 13:950737. <https://doi.org/10.3389/fmicb.2022.950737>
 43. Jeon J, Yong D. 2019. Two novel bacteriophages improve survival in *Galleria mellonella* infection and mouse acute pneumonia models infected with extensively drug-resistant *Pseudomonas aeruginosa*. *Appl Environ Microbiol* 85:e02900-18. <https://doi.org/10.1128/AEM.02900-18>
 44. Liu D, Van Belleghem JD, de Vries CR, Burgener E, Chen Q, Manasherob R, Aronson JR, Amanatullah DF, Tamma PD, Suh GA. 2021. The safety and toxicity of phage therapy: a review of animal and clinical studies. *Viruses* 13:1268. <https://doi.org/10.3390/v13071268>
 45. Bao J, Wu N, Zeng Y, Chen L, Li L, Yang L, Zhang Y, Guo M, Li L, Li J, Tan D, Cheng M, Gu J, Qin J, Liu J, Li S, Pan G, Jin X, Yao B, Guo X, Zhu T, Le S. 2020. Non-active antibiotic and bacteriophage synergism to successfully treat recurrent urinary tract infection caused by extensively drug-resistant *Klebsiella pneumoniae*. *Emerg Microbes Infect* 9:771–774. <https://doi.org/10.1080/22221751.2020.1747950>
 46. Eskenazi A, Lood C, Wubbolts J, Hites M, Balarjshvili N, Leshkasheli L, Askilashvili L, Kvachadze L, van Noort V, Wagemans J, Jayankura M, Chanishvili N, de Boer M, Nibbering P, Kutateladze M, Lavigne R, Merabishvili M, Pirnay J-P. 2022. Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant *Klebsiella pneumoniae*. *Nat Commun* 13:302. <https://doi.org/10.1038/s41467-021-27656-z>
 47. Qurat-ul-Ain H, Ijaz M, Siddique AB, Muzammil S, Shafique M, Rasool MH, Almatroudi A, Khurshid M, Chaudhry TH, Aslam B. 2021. Efficacy of phage-antibiotic combinations against multidrug-resistant *Klebsiella pneumoniae* clinical isolates. *Jundishapur J Microbiol* 14. <https://doi.org/10.5812/jjm.111926>
 48. Choi M, Hegerle N, Nkeze J, Sen S, Jamindar S, Nasrin S, Sen S, Permal-Booth J, Sinclair J, Tapia MD, et al. 2020. The diversity of lipopolysaccharide (O) and capsular polysaccharide (K) antigens of invasive *Klebsiella pneumoniae* in a multi-country collection. *Front Microbiol* 11:1249. <https://doi.org/10.3389/fmicb.2020.01249>
 49. Turner PE, Azeredo J, Buurman ET, Green S, Haaber JK, Haggstrom D, Kameda de Figueiredo Carvalho K, Kirchhelle C, Gonzalez Moreno M, Pirnay J-P, Portillo MA. 2024. Addressing the research and development gaps in modern phage therapy. *Phage* 5:30–39. <https://doi.org/10.1089/phage.2023.0045>
 50. Storms ZJ, Teel MR, Mercurio K, Sauvageau D. 2020. The virulence index: a metric for quantitative analysis of phage virulence. *Phage (New Rochelle)* 1:27–36. <https://doi.org/10.1089/phage.2019.0001>